Guardion Health Sciences Stockholders Urged to Vote Their Shares for October 22, 2021 Annual Meeting
Guardion Health Sciences, Inc. (Nasdaq: GHSI) is urging stockholders to vote their shares ahead of the Annual Meeting scheduled for October 22, 2021. Votes must be submitted by 11:59 PM ET on October 21, 2021. Key proposals include the election of five Directors, auditor approval, and executive compensation approval. Stockholders can contact Kingsdale Advisors for assistance with voting. The Company emphasizes the importance of every vote being counted. Further details are available in the Company's proxy statement.
- Encourages stockholders to participate in the voting process, enhancing shareholder engagement.
- Provides a clear deadline for voting, facilitating timely decision-making.
- None.
HOUSTON, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”), a clinical nutrition and diagnostics company that develops clinically supported nutrition, medical foods, supplements, and medical devices, urges stockholders to vote their shares for the Company’s Annual Meeting of Stockholders on October 22, 2021 by 11:59PM ET on October 21, 2021.
Stockholders who have any questions or need assistance voting their shares should contact Guardion’s proxy solicitor, Kingsdale Advisors, by calling toll-free at 1-866-229-8874 or via email at contactus@kingsdaleadvisors.com.
Stockholders are being asked to vote on the following Proposals:
- Election of five Director nominees
- Approval of Auditors
- Approval of the 2020 Named Executive Officer compensation.
The Company reminds stockholders that it is important that every vote, regardless of the number of shares, be counted. The Company’s proxy statement can be found here.
About Guardion Health Sciences, Inc.
Guardion Health Sciences, Inc. (Nasdaq: GHSI), is a clinical nutrition and diagnostics company. Guardion’s portfolio of science-based, clinically supported nutrition, medical foods, and diagnostic products support healthcare professionals, their patients, and consumers in achieving health goals. Guardion’s commercial and developmental initiatives are supported by equally impressive scientific and medical advisory boards, led by seasoned business executives and physicians with many years of experience. This combination of expertise and scientific knowledge forms the foundation of Guardion’s growing position within the eye care industry and the clinical nutrition marketplace. Information and risk factors with respect to Guardion and its business, including its ability to successfully develop and commercialize its proprietary products and technologies, may be obtained in the Company’s filings with the U. S. Securities and Exchange Commission (the “SEC”) at www.sec.gov.
Forward-Looking Statement Disclaimer
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by or that otherwise include the words “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans” and similar expressions or future or conditional verbs such as “will,” “should,” “would,” “may” and “could” are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements involve unknown risks and uncertainties that may individually or materially impact the matters discussed herein for a variety of reasons that are outside the control of the Company, including, but are not limited to, the Company’s ability to raise sufficient financing to implement its business plan, the integration of a new management team, the integration of one or more acquisitions and targets, the impact of the COVID-19 pandemic on the Company’s business, operations and the economy in general, the Company’s ability to successfully develop and commercialize its proprietary products and technologies, and the Company’s ability to maintain compliance with Nasdaq’s listing requirements. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company’s filings with the SEC, which are available at the SEC’s website (www.sec.gov). The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
CORE IR
Scott Arnold
516-222-2560
scotta@coreir.com
Media Relations Contact:
Jules Abraham
Director of Public Relations
CORE IR
917-885-7378
julesa@coreir.com
FAQ
What is the date of the Guardion Health Sciences Annual Meeting?
What proposals will be voted on during the GHSI Annual Meeting?
How can stockholders vote for the GHSI Annual Meeting?
Who can stockholders contact for assistance with voting their shares?
